COMP <GO>
RMD vs LLY // RETURN ON INVESTED CAPITAL (ROIC)
ResMed Inc. (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: RMD 7
— LLY 7
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: LLY
LAST: $229.94 (-9.05%) • MKT CAP: $35.56B
roic
22.90%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
roic
32.36%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RMD VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RMD | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.40% | 83.64% | -24.24 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 22.90% | 32.36% | -9.46 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 19.9x | 36.4x | -16.52 | RMD | /valuation <GO> |
| Free Cash Flow Yield | 4.67% | 2.30% | +2.37 | RMD | /fcf-yield <GO> |
| Operating Margin | 32.70% | 40.21% | -7.51 | LLY | /operating-margins <GO> |
| Net Profit Margin | 27.20% | 31.90% | -4.70 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 9.80% | 45.51% | -35.71 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.87% | 0.49% | +0.38 | RMD | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.49 | 9.29 | +3.20 | RMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 6.77% | -0.07 | RMD | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.8 | 77.9 | -36.12 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.93 | 0.51 | +0.42 | RMD | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.6x | 26.3x | -2.65 | RMD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $35.56B | $1.33T | -$1.30T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RMD REV | LLY REV | RMD GROSS % | LLY GROSS % | RMD FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.15B | $65.18B | 59.4% | 83.0% | $1.66B | $16.81B |
| FY 2024 | $4.69B | $45.04B | 56.7% | 81.3% | $1.30B | $8.82B |
| FY 2023 | $4.22B | $34.12B | 44.0% | 79.3% | $503.3M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RMD // BETA 0.93
LLY // BETA 0.51